Drug intelligence / Profile preview

bosutinib

Development stage: Approved
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

Bosutinib is a tyrosine kinase inhibitor used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It works by blocking the Bcr-Abl kinase and Src-family kinases, which are involved in the growth of cancer cells. Bosutinib is typically administered orally once daily with food.

Brand names: BosulifBosuvi
Other names: bosutinib monohydrate4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Targets

ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)SFK (SRC family kinases)EPHB2 (Ephrin type-B receptor 2)EGFR T790M (Epidermal growth factor receptor T790M mutant)PDGFR (PDGFR family)KIT (c-KIT proto-oncogene receptor tyrosine kinase)

Beyond the preview

Go deeper on bosutinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bosutinib.

Explore the full profile